Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le vendredi 19 juillet 2013
Doi : 10.1016/j.jaad.2013.05.011
An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma
 

Kevin O’Bryan, MD a, William Sherman, MD b, George W. Niedt, MD c, Bret Taback, MD d, Spiros Manolidis, MD e, Antai Wang, PhD f, Désirée Ratner, MD g,
a Department of Dermatology, Division of Dermatologic Surgery, Columbia University Medical Center, New York, New York 
b Department of Internal Medicine, Division of Oncology, Columbia University Medical Center, New York, New York 
c Department of Dermatology, Division of Dermatopathology, Columbia University Medical Center, New York, New York 
d Department of Surgery, Columbia University Medical Center, New York, New York 
e Department of Head and Neck Surgery, Albert Einstein School of Medicine, New York, New York 
f Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York 
g Department of Dermatology, Beth Israel Medical Center and St Luke’s and Roosevelt Hospitals, New York, New York 

Reprint requests: Désirée Ratner, MD, Beth Israel Cancer Center West, 325 W 15 St, New York, NY 10011.
Abstract
Background

No established standard of care exists for aggressive cutaneous squamous cell carcinoma (CSCC).

Objective

We sought to establish an aggressive CSCC management protocol by reviewing high-risk CSCC (HCSCC) and very high-risk CSCC (VCSCC) cases at our institution.

Methods

This was a retrospective review of all CSCC cases treated at our institution.

Results

A total of 27 patients were identified of 1591 cases treated between 2000 and 2011. Four patients with HCSCC received surgery alone and 1 received surgery and radiation. All remain disease free (median follow-up 5 years). Among patients with VCSCC, 4 received surgery alone: 1 (25%) showing a complete response and 3 (75%) showing disease progression. Eleven received surgery and radiation: 4 (36.4%) with complete response (median follow-up 3 years) and 7 (63.6%) with disease progression (median time to recurrence 6 months). Six received surgery and cetuximab: 3 (50%) had a complete response (median follow-up 3 years), 2 (33%) had disease progression, and 1 (14%) could not be assessed because of inability to tolerate infusions. One patient received surgery, cetuximab, and radiation, and remains disease-free after 4 years.

Limitations

Lack of randomization, blinding, a true control arm, or standardization of treatment protocols are limitations.

Conclusions

Patients with very HCSCC may have improved outcomes with surgery and adjuvant cetuximab.

The full text of this article is available in PDF format.

Key words : carcinoma, cetuximab, cutaneous, epidermal growth factor receptor, radiation, skin, squamous

Abbreviations used : CR, CSCC, EGFR, HCSCC, SCC, SCCHN, VCSCC



 Funding sources: None.
 Conflicts of interest: None declared.
 Presented at the 2012 American College of Mohs Surgery Annual Meeting, Chicago, IL, May 2012.



© 2013  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline